Ototoxic effect of erythromycin therapy.
Thirty-two cases of sudden, symmetrical, high-frequency, sensorineural hearing loss associated with intravenous (IV) and oral erythromycin therapy have been published since 1973. We treated a patient with reversible ototoxicity associated with IV erythromycin for the treatment of legionnaire's disease.
D001299:Audiometry; D004917:Erythromycin / Q000009:adverse effects*; D005260:Female; D006319:Hearing Loss, Sensorineural / Q000139:chemically induced* / Q000175:diagnosis; D006801:Humans; D008875:Middle Aged
D004917:Erythromycin